The importance of the epigenome in tumour development and recurrence
I aim to develop methods to reverse epigenetic anomalies in cancer stem cells (CSCs) to switch off the unlimited cell division and cancer growth and to understand the involvement of epigenetics in tumour development and recurrence...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Proyectos interesantes
BERG
BERG Biomedical Epigenomics Research Group
100K€
Cerrado
EPIGBRCASTEM
THE EPIGENOME OF BREAST CANCER STEM CELLS
100K€
Cerrado
PID2021-125282OB-I00
USO DE APROXIMACIONES DE CELULA UNICA PARA DECIFRAR LA EPIGE...
472K€
Cerrado
CanSel
Highly selective customizable therapy for metastatic tumors
166K€
Cerrado
BCSC-ST
Breast cancer stem like cells specific vulnerabilities focu...
195K€
Cerrado
SAF2010-17935
DISEÑO Y SINTESIS DE NUEVOS MODULADORES DE ENZIMAS EPIGENETI...
363K€
Cerrado
Información proyecto EPIBRAIN
Líder del proyecto
GOETEBORGS UNIVERSITET
No se ha especificado una descripción o un objeto social para esta compañía.
TRL
4-5
Presupuesto del proyecto
100K€
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
I aim to develop methods to reverse epigenetic anomalies in cancer stem cells (CSCs) to switch off the unlimited cell division and cancer growth and to understand the involvement of epigenetics in tumour development and recurrence. Epigenetic alterations are observed at the earliest stages of neoplasia within stem cells. Importantly, the alterations are reversible and can potentially be treated. In children, brain tumours are the leading cause of cancer-related mortality and morbidity. There are severe side-effects from treatment and survivors often experience substantial long-term problems. In vitro cultures of CSCs are indispensable tools for functional analyses and development of new therapies. However, up to now, paediatric CSC cultures have not been available. My unique cultures now enable us to study this disease closer. Induce differentiation of the CSCs will turn them less proliferative and less tumourigenic. Hence, I will screen for drugs that induce differentiation and determine the role epigenetics has on the stability of the specific differentiation stages. In addition, I will explore the relevance of the epigenome in tumour development by removing epigenetic marks through reprogramming the cells into induced pluripotent stem cells. These analyses will highlight target genes and pathways that are involved in the differentiation process. Furthermore, biomarkers will be implemented and I will study radiation-induced long-term effects to increase survival, quality of life and reduce adverse side-effects from treatment.